文献速递消化道肿瘤与早癌消化内镜

欧洲儿童癌症五年生存者消化系统肿瘤风险:PanCareSurFup研究

Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study.
PubMed 文献 · Gut · 2020-11-02

该研究纳入欧洲12国69 460例儿童癌症五年生存者,量化消化系统后续原发肿瘤风险。共诊断427例消化系统肿瘤,肾母细胞瘤与霍奇金淋巴瘤生存者风险最高,结直肠癌风险约为一般人群7倍,55岁时累积发病率与有两个一级亲属患结直肠癌者相当。

要点

  • 肾母细胞瘤和霍奇金淋巴瘤生存者消化系统肿瘤风险最高
  • 两者结直肠癌风险约为一般人群7倍,55岁时累积发病率2.3%
  • 建议对肾母细胞瘤和霍奇金淋巴瘤生存者考虑55岁前结肠镜监测

核心结论

  • 肾母细胞瘤和霍奇金淋巴瘤生存者消化系统后续原发肿瘤风险显著增高,结直肠癌风险与有两个一级亲属患结直肠癌的一般人群相当。

研究设计与样本

  • PanCareSurFup队列纳入欧洲12国69 460例儿童癌症五年生存者,采用标准化发病比、绝对超额风险和累积发病率量化消化系统后续原发肿瘤风险。

主要发现

  • 共诊断427例消化系统后续原发肿瘤(214例结直肠、62例肝脏、48例胃、44例胰腺、59例其他),分布于413例生存者。
  • 肾母细胞瘤生存者SIR为12.1(95%CI 9.6至15.1),霍奇金淋巴瘤生存者SIR为7.3(95%CI 5.9至9.0),风险最高。
  • 肾母细胞瘤生存者累积发病率随年龄增长最陡,55岁时达7.4%,60岁时达9.6%(一般人群预期1.0%)。
  • 结直肠后续原发肿瘤中,肾母细胞瘤和霍奇金淋巴瘤生存者风险最高,均为预期的7倍。
  • 55岁时,肾母细胞瘤(95%CI 1.4至3.9)和霍奇金淋巴瘤(95%CI 1.6至3.2)生存者结直肠后续原发肿瘤累积发病率均为2.3%。

关键数值与推荐

  • 肾母细胞瘤生存者消化系统后续原发肿瘤SIR 12.1(95%CI 9.6至15.1)。
  • 霍奇金淋巴瘤生存者消化系统后续原发肿瘤SIR 7.3(95%CI 5.9至9.0)。
  • 肾母细胞瘤生存者55岁时累积发病率7.4%,60岁时9.6%,一般人群预期1.0%。
  • 肾母细胞瘤和霍奇金淋巴瘤生存者结直肠后续原发肿瘤风险均为预期的7倍,55岁时累积发病率均为2.3%。

临床怎么用

  • 许多欧洲国家推荐有结直肠癌家族史者在55岁前接受结肠镜监测,但肾母细胞瘤和霍奇金淋巴瘤生存者虽风险相当却未纳入推荐。
  • 临床应认真考虑对肾母细胞瘤和霍奇金淋巴瘤生存者实施结肠镜监测,同时需进一步评估其获益、危害和成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survivors of childhood cancer are at risk of subsequent primary neoplasms (SPNs), but the risk of developing specific digestive SPNs beyond age 40 years remains uncertain. We investigated risks of specific digestive SPNs within the largest available cohort worldwide. METHODS: The PanCareSurFup cohort includes 69 460 five-year survivors of childhood cancer from 12 countries in Europe. Risks of digestive SPNs were quantified using standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence. RESULTS: 427 digestive SPNs (214 colorectal, 62 liver, 48 stomach, 44 pancreas, 59 other) were diagnosed in 413 survivors. Wilms tumour (WT) and Hodgkin lymphoma (HL) survivors were at greatest risk (SIR 12.1; 95% CI 9.6 to 15.1; SIR 7.3; 95% CI 5.9 to 9.0, respectively). The cumulative incidence increased the most steeply with increasing age for WT survivors, reaching 7.4% by age 55% and 9.6% by age 60 years (1.0% expected based on general population rates). Regarding colorectal SPNs, WT and HL survivors were at greatest risk; both seven times that expected. By age 55 years, 2.3% of both WT (95% CI 1.4 to 3.9) and HL (95% CI 1.6 to 3.2) survivors had developed a colorectal SPN-comparable to the risk among members of the general population with at least two first-degree relatives affected. CONCLUSIONS: Colonoscopy surveillance before age 55 is recommended in many European countries for individuals with a family history of colorectal cancer, but not for WT and HL survivors despite a comparable risk profile. Clinically, serious consideration should be given to the implementation of colonoscopy surveillance while further evaluation of its benefits, harms and cost-effectiveness in WT and HL survivors is undertaken.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Reulen RC, Wong KF, Bright CJ, et al. Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study. Gut. 2020. PMID: 33139271. doi:10.1136/gutjnl-2020-322237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。